Product logins

Find logins to all Clarivate products below.


Otsuka -Therapeutic Portfolios | Genitourinary | Company & Drug | Global | 2024

  • The document complements our standalone (detailed) company profile (which emphasis on clinical aspects more) by adding the business facet covering overall strategy, Geographical focus, Therapy area evolution within the portfolio, SWOT analysis- and how the company’s business has evolved in the last couple of years.
  • The document gives a bird eyes view about the expected sales performance of the company covering the top-performing brands and therapy area focus based on their adopted business strategy. And how the company is fairing compared to its peers and what ranking changes are expected by the end of the forecast period.

Related Market Assessment Reports

Report
Non-Small-Cell Lung Cancer | Disease Landscape & Forecast | G7 | 2024
The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.), which…
Report
Squamous Cell Carcinoma of the Head and Neck | Disease Landscape & Forecast | G7 | 2024
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Ovarian Cancer | Disease Landscape & Forecast | G7 | 2024
The treatment of ovarian cancer has been transformed by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (Zejula; GSK), and…
Report
Systemic Lupus Erythematosus – Geographic Focus: China – China In-Depth – Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs or systems in the body. The treatment goals of physicians who manage SLE patients differ depending on…
Report
Urticaria | Disease Landscape & Forecast | G7 | 2024
The urticaria drug market is dominated by oral medications—including steroids and second-generation, nondrowsy antihistamines—which are prescribed for both chronic inducible urticaria (CIndU)…